BEACON EMR HIPAA Disclaimer Site Map Social Media
BayCare Health System
Community Benefit Financial Assistance Policy Quality Report Card Health Library News Doctor Connect Find Us
Services Hospitals Find A Doctor Classes & Events About Us Careers Contact Us Get E-Newsletter
HealthDay Articles & Information
 Back  Back


May We Help You?
 

Call 1-877-692-2922
Monday-Friday, 8am to 5pm

Persons with hearing and speech disabilities can reach the above number through TDD and other specialized equipment by calling the Florida Relay Service at 711.

Contact Us
Send 
e-mail
Search jobs


Decrease (-) Restore Default Increase (+) Font Size
Print    Email
Search Health Information   

Gattex Approved for Short Bowel Syndrome

Provides nutrition for people with surgically removed intestine

FRIDAY, Dec. 21 (HealthDay News) -- Gattex (teduglutide) has been approved by the U.S. Food and Drug Administration to treat nutritional problems caused by short bowel syndrome, which results when the small and/or large intestine are surgically removed.

Extensive removal of the intestines can lead to poor absorption of fluids and nutrients, the FDA said Friday in a news release.

Gattex is a once-daily injection that helps improve intestinal absorption. Two other drugs, somatropin and glutamine, have been FDA-approved to help treat short bowel disorder.

People who take Gattex may be at increased risk of developing colon cancer, intestinal polyps, gallbladder disease, biliary tract disease or pancreatic disease, the agency said.

The drug was evaluated in two clinical studies and two extension studies. The most common side effects reported were abdominal pain, injection site reactions, nausea, headache and upper respiratory tract infection.

Gattex is marketed by NPS Pharmaceuticals, based in Bedminster, N.J.

More information

The U.S. National Library of Medicine has more about short bowel syndrome.


Copyright © 2012 HealthDay. All rights reserved.


Serving The Tampa Bay Area © Copyright 2014 BayCare Health System